Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728351 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 317
- Enrollment target
NCT00728351 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 317 participants.
The verdict
NCT00728351, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 317 participants
- Enrollment target
Study Summary
The present study is designed to evaluate the efficacy and safety of fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) in patients with type 2 diabetes inadequately controlled with prior metformin monotherapy.
Interventions
- DRUG metformin
- DRUG vildagliptin + metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00728351
The ClinicalTrials.gov registry entry for NCT00728351 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which metformin is the first listed.
NCT00728351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00728351 about?
NCT00728351 is a clinical study titled "Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)". The present study is designed to evaluate the efficacy and safety of fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) in patients with type 2 diabetes inadequately controlled with prior metformin monotherapy.
What is the current status of trial NCT00728351?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 317 participants. The study started on 2008-06.
What interventions are being tested in trial NCT00728351?
The interventions under investigation include: metformin (DRUG), vildagliptin + metformin (DRUG).
Who is sponsoring clinical trial NCT00728351?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.